The prospect of specific therapies that induce complete molecular genetic remission, analogous to tyrosine kinase inhibitor therapy for BCR::ABL1-postiive CML, remains a compelling approach in the pursuit of the best clinical outcomes for MF. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.